Should patients with advanced colorectal cancer be treated with chemotherapy?

European Journal of Cancer Part A

Volumn 33, Issue 6, 1997, Pages 815-817

  Blijham, G H ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLINIC ACID; GYRASE INHIBITOR; METHOTREXATE; RALTITREXED;

ADVANCED CANCER; CANCER SURVIVAL; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; HUMAN; HUMAN CELL; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SURVIVAL TIME;

EID: 0030842336     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0959-8049(97)00077-4     Document Type: Article

References (41)

1. Simon R. Importance of prognostic factors in cancer clinical trials. Cancer Treat Rep 1984, 68, 185-192.
2. Marsoni S, Wittes R. Clinical development of anticancer agents-a National Cancer Institute Perspective. Cancer Treat Rep 1984, 68, 77-85.
3. Leichmann CG, Fleming TR, Muggia FM, et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group Study. J Clin Oncol 1995, 13, 1303-1311.
4. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992, 10, 896-903.
5. Piedbois P, Buyse M, Blijham GH, et al. Meta-analysis of randomized trials testing the biochemical modulation of 5-fluorouracil by methrotrexate in metastatic colorectal cancer. J Clin Oncol 1994, 12, 960-969.
6. Allen-Mersh TG, Earlam S, Fordy C, Abrams K, Houghton J. Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver métastases. Lancet 1994, 344, 1255-1260.
7. Hafström L, Engarâs B, Holmberg ST, et al. Treatment of liver métastases from colorectal cancer with hepatic artery occlusion, intraportal 5-fluorouracil infusion, and oral allopurinol. A Randomized Clinical Trial. Cancer 1994, 74, 2749-2756.
8. Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. J Clin Oncol 1992, 10, 904-911.
9. Schreithauer W, Rosen H, Kornek GV, Sebesta C, Depisch D. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br Med J 1993, 306, 752-5.
10. Glimelius B. Biochemical modulation of 5-fluorouracil: A randomized comparison of sequential methotrexate, 5-fluorouracil and leucovorin versus sequential 5-fluorouracil and leucovorin in patients with advanced symptomatic colorectal cancer. Ann Oncol 1993, 4, 235-240.
11. Blijham GH, Wagener Th, Wils J, et al. Modulation of highdose infusional 5-fluorouracil by low-dose methotrexate in patients with advanced or metastatic colorectal cancer: final results of a randomized EORTC study. J Clin Oncol 1996, 14, 2266-2273.
12. Buroker TR, O'Connell MJO, Wieand HS, et al. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 1994, 12, 14-20.
13. Zalcberg JR, Siderov J, Simes J. The role of 5-fluorouracil dose in the adjuvant therapy of colorectal cancer. Ann Oncol 1996, 7, 41-46.
14. Lokich JJ, Ahlgren JD, Gullo JJ, et al. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in matastatic colorectal cancer: a Mid-Atlantic Oncology Program study. J Clin Oncol 1989, 7, 425-432.
15. Köhne CH, Hecker H, Schöffski P, Wilke H, Schubert U, Schmoll HJ. Weekly high dose infusionaal (C1)5-FU plus folinic acid (FA) has major impact on survival in patients with advanced colorectal cancer. Results of multivariate analysis using recpam. Proc Am Soc Clin Oncol 1996, 15, 201 (abstract 445).
16. Seitz JF, Cunnigham D, Rath U, et al. Final results and survival data of a large randomised trial of tomudex in advanced colorectal cancer (ACC) confirm comparable efficacy to 5-fluorouracil plus leucovorin (5FU + LV). Proc Am Soc Clin Oncol 1996, 15, 201 (abstract 446).
17. Moertel CG, Fleming TR, Macdonald JS, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995, 122, 321-326.
18. IMPACT Investigators (Labianca R, Marsoni S, Pancera G, et al.) Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995, 345, 939-944.
19. Wolmark N, Rockette H, Mamounas EP, et al. The relative efficacy of 5FU + leucovorin, 5FU + levamisole and 5FU + leucovorin + levamisole in patients with Dukes' B and C carcinoma of the colon: first report of NSABP C-04. Proc Am Soc Clin Oncol 1996, IS, 460.
20. Piedbois P, Buyse M, Gray R, et al. Portal vein infusion is an effective adjuvant treatment for patients with colorectal cancer. Proc Am Soc Clin Oncol 1995, 14, 444 (abstract).
21. Scheithauer W, Rosen H, Kornek GV, et al. Randomized comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BrMedJ 1993, 306, 752-755.
22. Allen-Mersh TG, Earlam S, Fordy C, et al. Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver métastases. Lancet 1994, 344, 1255-1260.
23. The Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer-a randomized trial. J Clin Oncol 1992, 10, 904-911.
24. Middleton G, Cunningham D. Current options in the management of gastrointestinal cancer. Ann Oncol 1995, 6 (Suppl. 1), 817-826.
25. Macdonald JS, on behalf of the International Working Group in Colorectal Cancer. The treatment and management of advanced colorectal cancer: the Colorectal Cancer Pathway Review. Proc Am Soc Clin Oncol 1996, IS, 563 (abstract).
26. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engljmed 1990, 322, 352-358.
27. Poon MA, O'Connell MJ, Moertel CG, et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma, J Clin Oncol 1989, 7, 1407-1417.
28. Buyse M, Piedbois P. Meta-analysis: use and misuse. J Clin Oncol 1993, 11, 382.
29. Michels KB. Quo vadis meta-analysis? A potentially dangerous tool if used without adequate rules. In De Vita VT, Hellman S, Rosenberg SA, eds. Imponant Advances in Oncology. Lippincott, Philadelphia, 1992, 243-248.
30. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992, 10, 896-903.
31. Advanced Colorectal Cancer Meta-Analysis Project. Metaanalysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. J Clin Oncol 1994, 12, 960-969.
32. Kemeny N, Buyse M, Rougier P, et al. A meta-analysis of hepatic arterial infusion in patients with liver métastases from colorectal cancer. Proc Am Soc Clin Oncol 1996, 15, 448 (abstract).
33. Moertel CG. Chemotherapy for colorectal cancer. N Engl J Med 1994, 326, 1136-1142.
34. Kemeny N. Chemotherapy for colorectal carcinoma: one small step forward, one step backward. J Clin Oncol 1995, 13, 1287-1290.
35. American Society of Clinical Oncology. Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol 1996, 14, 671-679.
36. Poon MA, O'Connell MJ, Wieand HS, et al. Biochemical modulation of Fluorouracil with Leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 1991, 9, 1967-1972.
37. Sobrero A, Aschele C, Guglielmi A, et al. High activity and low toxicity of alternating bolus and continuous infusion 5-fluorouracil with schedule-oriented biochemical modulation in advanced colorectal cancer. Proc Am Soc Clin Oncol 1994, 13, 588 (abstract).
38. Rothenberg ML, Moore MJ, Cripps MC, et al. A phase II trial of gemcitabine in patients with 5FU-refractory pancreas cancer. Ann Oncol 1996, 7, 347-353.
39. Glimelius B, Hoffinan K, Graf W, et al. Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. Ann Oncol 1995, 6, 267-274.
40. Zalcberg JR, Cunningham D, Van Cutsem E, et al. ZD 1694: a novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. J Clin Oncol 1996, 14, 716-721.
41. Rothenberg ML, Eckardt JR, Kühn JG, et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 1996, 14, 1128-1135.